Aetion
Christophe Berthoux is a seasoned executive with extensive experience in the healthcare and clinical research industries. Currently serving as the Founder and Board Member of FutureMeds since September 2020 and as Chairman of the Board for the IMAGE ANALYSIS GROUP since September 2018, Christophe has also held the position of Chief Executive Officer at NAMSA from March 2021 to May 2024. Previous roles include Non-Executive Director at Citoxlab and Chief Executive Officer at Synexus Clinical Research Ltd. From January 2005 to September 2010, Christophe worked at Charles River Laboratories, where responsibilities included Executive Vice President of Sales & Marketing, Chief Commercial Officer, Senior Vice President of RMS Operations, and General Manager. Christophe holds an Executive MBA in Management from Purdue University's Daniels School of Business and a Doctor of Veterinary Medicine degree from Ecole nationale vétérinaire de Lyon.
This person is not in the org chart
This person is not in any teams
Aetion
9 followers
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era.